Holen Sie sich die Stockscreener-App
147.41
1.68%
-1.9233
Schlusskurs vom Vortag:
$149.33
Offen:
$147.1
24-Stunden-Volumen:
519.09K
Relative Volume:
0.17
Marktkapitalisierung:
$31.42B
Einnahmen:
$606.42M
Nettoeinkommen (Verlust:
$-1.28B
KGV:
-23.02
EPS:
-6.403
Netto-Cashflow:
$-997.58M
1W Leistung:
-7.68%
1M Leistung:
-4.65%
6M Leistung:
+1.05%
1J Leistung:
+80.04%
1-Tages-Spanne:
$145.00
$148.87
1-Wochen-Bereich:
$145.00
$161.13
52-Wochen-Spanne:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
147.34 | 31.85B | 606.42M | -1.28B | -997.58M | -6.403 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.83 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.62 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
759.38 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.79 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
307.99 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
William Blair Investment Management LLC Has $223.94 Million Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Incorporated (INSM) Enters 2026 With Momentum - Finviz
INSM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Insmed (INSM) director gifts shares and details family holdings - Stock Titan
Insmed, Inc. Experiences Revision in Its Stock Evaluation Amid Financial Performance Trends - Markets Mojo
Artisan Partners Limited Partnership Grows Stock Position in Insmed, Inc. $INSM - MarketBeat
Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In - Finviz
Westfield Capital Management Co. LP Lowers Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Thornburg Investment Management Inc. Trims Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Stock Hits Day Low of $148.24 Amid Price Pressure - Markets Mojo
INSMED Chief Legal Officer Sells Shares Worth Over $3.8 Million - TradingView
Insmed (INSM) Q4 2025 Earnings Call Transcript - AOL.com
HC Wainwright Forecasts Insmed's Q3 Earnings (NASDAQ:INSM) - MarketBeat
Brown Advisory Small-Cap Growth Fund's Insmed Inc(INSM) Holding History - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
H.C. Wainwright Remains a Buy on Insmed (INSM) - The Globe and Mail
INSM Stock Rating: Mizuho Lowers Price Target Amid Consistent Ou - GuruFocus
Mizuho Issues Pessimistic Forecast for Insmed (NASDAQ:INSM) Stock Price - MarketBeat
Insmed Incorporated (INSM) Gained from Its Lead Product ARIKAYCE - Yahoo Finance
HC Wainwright Comments on Insmed's Q1 Earnings (NASDAQ:INSM) - MarketBeat
Insmed chair and CEO Lewis sells $1.6m in stock By Investing.com - Investing.com Nigeria
Insmed chair and CEO Lewis sells $1.6m in stock - Investing.com
Insmed (INSM) Is Up 6.9% After BRINSUPRI Sales Beat Expectations And 2026 Target SetWhat's Changed - Yahoo Finance
H.C. Wainwright reiterates Buy on Insmed stock, $230 target By Investing.com - Investing.com UK
William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed (INSM) CEO Lewis exercises options and sells 10,699 shares - Stock Titan
INSM: HC Wainwright & Co. Reiterates Buy Rating with $230 PT | I - GuruFocus
Mizuho Securities Cuts Insmed Price Target to $204 From $211, Maintains Outperform Rating - marketscreener.com
Insmed (NASDAQ:INSM) Given Buy Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy on Insmed stock, $230 target - Investing.com
Patient Square Capital LP Reduces Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Gets UK Marketing Authorization for Non-Cystic Fibrosis Bronchiectasis Treatment - marketscreener.com
Hillsdale Investment Management Inc. Sells 7,000 Shares of Insmed, Inc. $INSM - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Insmed (INSM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and Insmed (INSM) - The Globe and Mail
Wells Fargo Lowers Price Target for Insmed (INSM) Amid Overweigh - GuruFocus
Breaking Down Insmed: 16 Analysts Share Their Views - Benzinga
Wall Street Analysts Think Insmed (INSM) Could Surge 33.6%: Read This Before Placing a Bet - Finviz
Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View - Bitget
Insmed Q4 Reinforces Confidence in Brinsupri Growth, RBC Says - marketscreener.com
Insmed May Top Revenue Target for Bronchiectasis Drug Brinsupri, Morgan Stanley Says - marketscreener.com
Insmed Incorporated (NASDAQ:INSM) Q4 2025 Earnings Call Transcript - Insider Monkey
Skandinaviska Enskilda Banken AB publ Grows Position in Insmed, Inc. $INSM - MarketBeat
Morgan Stanley Lifts Price Target on Insmed to $166 From $162, Keeps Equalweight Rating - marketscreener.com
Insmed, Inc. $INSM Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
Fiera Capital Corp Grows Stock Position in Insmed, Inc. $INSM - Defense World
Insmed (INSM) Poised for 2026 Upside With Potential $1.3B Arikayce Sales Boost, Roth/MKM Initiates Buy - Finviz
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed: Q4 Earnings Snapshot - theheraldreview.com
Insmed jumps as new drug launch momentum drives bullish 2026 revenue outlook - Quiver Quantitative
Insmed Inc (INSM) Q4 2025 Earnings Call Highlights: Strong Brin Suri Launch and Promising 2026 ... By GuruFocus - Investing.com Canada
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insmed Inc-Aktie (INSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Smith Michael Alexander | Chief Legal Officer |
Feb 24 '26 |
Sale |
155.77 |
24,774 |
3,859,157 |
51,871 |
2.60%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):